Takayasu arteritis (TA) is an idiopathic inflammatory vasculitis mostly affecting young females in the second or third decades of life. Corticosteroids and conventional immunosuppressants remain the mainstay of treatment for TA, but refractory cases are dealt with biological agents. The high cost and longer duration of therapy are issues of concern. Here, we report a case of a patient with refractory TA who underwent successful treatment with tocilizumab, a humanized monoclonal antibody against interleukin-6 receptor.
JohnstonSLLockRJGompelsMM.Takayasu arteritis: A review. J Clin Pathol. 2002;55(7):481-486.
2.
PatnaikSPatnaikAN.Emerging drug therapies for refractory Takayasu arteritis. J Indian Coll Cardiol. 2014;4(4):218-221.
3.
VaideeswarPDeshpandeJR.Pathology of Takayasu arteritis: A brief review. Ann Pediatr Cardiol. 2013;6(1):52.
4.
LvNWangZDangAHLA-DQA1, DQB1 and DRB1 alleles associated with Takayasu arteritis in the Chinese Han population. Hum Immunol. 2015;76(4):241-244.
5.
KeserGDireskeneliHAksuK.Management of Takayasu arteritis: A systematic review. Rheumatology. 2013;53(5):793-801.
6.
SilverM.Takayasu’s arteritis: An unusual cause of stroke in a young patient. West J Emerg Med. 2012;13(6):484.
7.
CliffordAHoffmanGS.Recent advances in the medical management of Takayasu arteritis: An update on use of biologic therapies. Curr Opin Rheumatol. 2014;26(1):7-15.
8.
NishimotoNNakaharaHYoshio-HoshinoNMimaT.Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008;58(4):1197-1200.
9.
CampbellLChenCBhagatSSParkerRAÖstörAJ.Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: A systematic literature review and meta-analysis of randomized controlled trials. Rheumatology. 2010;50(3):552-562.
